Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s ...

At just 29, Melbourne mum Erin Kelly is facing the heartbreaking reality that she's living on borrowed time. A single parent ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Recent developments in major pharmaceutical companies indicate a mixed outlook. Biogen's Leqembi shows promising sales, while Haleon and Novo Nordisk face setbacks due to weak U.S. demand and ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.